Peer-reviewed veterinary case report
Etodolac reduces jaw joint arthritis in dogs after surgery
By Miyamoto, Hizuru et al.·Published in Journal of cranio-maxillo-facial surgery : official publication of the European Association for Cranio-Maxillo-Facial Surgery·2007·Department of Diagnosis & Therapeutic Science, Japan·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: The effect of etodolac on experimental temporomandibular joint osteoarthritis in dogs.
- Species:
- dog
Plain-English summary
A group of adult beagle dogs developed osteoarthritis in their jaw joints after surgery. Half of the dogs received a daily dose of etodolac, a medication used to relieve pain and inflammation, while the other half received a placebo. After eight weeks, the dogs treated with etodolac showed significantly less severe joint damage compared to those that did not receive the medication. This suggests that etodolac may help manage osteoarthritis in dogs and potentially in humans as well.
People also search for: dog jaw pain treatment · beagle osteoarthritis medication · etodolac for dogs arthritis
Abstract
PURPOSE: The purpose of this study was to test the effect of etodolac on a dog model of osteoarthritic temporomandibular joints (TMJ). MATERIAL AND METHODS: Ten adult beagle dogs underwent surgery to induce osteoarthritis in the right TMJ, and were then randomly divided into two groups each of 5 dogs. From 2 to 6 weeks after surgery, the dogs in group 1 (control group) were given an empty gelatin capsule daily, and the dogs in group 2 (study group) were given 15 mg/kg of etodolac daily. All joints were examined radiologically and histologically 8 weeks postoperatively. RESULTS: In group 1, the operated right joints showed severe osteoarthritic changes in the condyle and severe morphological differences in comparison with the unoperated (left joint). Group 2 showed fewer morphological differences between the unoperated control (left) and the operated (right) TMJ. Osteoarthritic changes in the TMJ were significantly less severe in group 2 (etodolac) than in group 1. CONCLUSION: Oral administration of etodolac at a dose of 15 mg/kg minimized the continuation of experimentally induced osteoarthritic changes in the canine TMJ, when compared with the placebo. Thus, etodolac may play a role in preventing progression of human TMJ osteoarthritis.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/17964178/